JPMorgan raised the firm’s price target on Johnson & Johnson to $195 from $185 and keeps a Neutral rating on the shares. The firm left its large cap biopharma estimates largely unchanged but adjusted price targets on a move to December 2026 from December 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots
- Kenvue Stock (KVUE) Up after CEO Met Health Secretary to Kick Tylenol Off Autism Report
- Protagonist Therapeutics initiated with an Outperform at Leerink
- Protagonist Therapeutics announces icotrokinra application submitted to EMA
- Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads